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share pathways of T-cell and innate
immune activation, and therefore the
role of streptococci in plaque psoriasis
ultimately requires further elucidation.
Despite the lack of established caus-
ality between chronic plaque psoriasis
and streptococcal infection, the theore-
tical link between disease pathogenesis
and preceding antigen exposure is pro-
mising. Globally, populations are
exposed to a heterogeneous multitude
of environmental and infectious anti-
gens. Regional differences in antigen
exposure may thus account for some of
the variation observed in the incidence
and prevalence of psoriasis, and it may
be that the same genes that now lead to
psoriasis also confer or in the past
conferred a selective advantage against
skin infection.
Concluding remarks
As Parisi et al. (2012) indicate in this
issue, a number of narrative reviews of the
epidemiology of psoriasis have been
published, but the prevalence and
incidence of psoriasis worldwide is not
yet well characterized. Limitations of this
study stem from substantial methodo-
logical differences among the cited
studies. In addition, as acknowledged by
the authors, variability in the identification
of psoriasis cases and prevalence mea-
sures (point, period, or lifetime) have also
limited this analysis because of hetero-
geneity in data collection methods.
Nevertheless, global epidemiological
studies have paved the way for greater
appreciation of the disease burden of
psoriasis and have pointed out the great
need to improve our skin disease epide-
miology on both national and global
basis. With further epidemiological
characterization, future investigation
may ultimately shed light on additional
nuances of the pathogenesis of this
common but complex disorder.
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Dacarbazine in Melanoma: From a
Chemotherapeutic Drug to
an Immunomodulating Agent
Selma Ugurel1,2, Annette Paschen3 and Ju¨rgen C. Becker2
Chemotherapeutic drugs are clinically used to treat cancer because of their
cytotoxic activities against tumor cells. Recently, however, evidence is accumu-
lating—including the report of Hervieu et al. (2012) in the current issue of The
Journal of Investigative Dermatology—indicating that at least some of these drugs
have broader activities and that they should also be considered immuno-
modulatory agents. Indeed, Hervieu demonstrates that dacarbazine (DTIC)
exerts immunostimulatory effects by inducing local activation of natural killer
(NK) and T cells, suggesting that upon treatment with DTIC, the tumor participates
in the initiation of an immune response: (i) DTIC treatment elicits the expression
of ligands of the immunoreceptor NKG2D on melanoma cells; (ii) engagement of
the ligands by NKG2D on NK cells leads to their activation, allowing enhanced
tumor-cell killing and the release of IFN-g; and (iii) IFN-g in turn upregulates
major histocompatibility complex class I expression on tumor cells, which favors
their recognition by cytotoxic CD8þ T lymphocytes (CTLs).
Journal of Investigative Dermatology (2013) 133, 289–292. doi:10.1038/jid.2012.341
For decades, chemotherapy with dacarba-
zine (DTIC) has served as the therapeutic
standard in patients with inoperable
metastatic melanoma, despite the fact
that a survival benefit by this drug has
never been demonstrated in clinical trials,
making its effectiveness still a matter
of doubt. Nevertheless, until recently,
other treatment regimens tested against
DTIC in clinical phase-III trials failed
to demonstrate superiority in patient
survival. Fortunately, however, this has
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changed, as two agents, using different
therapeutic strategies, the immunother-
apeutic ipilimumab (Hodi et al., 2010)
and the kinase inhibitor vemurafenib
(Flaherty et al., 2010), demonstrated sig-
nificant prolongations in patient survival.
Both drugs have been registered for the
treatment of advanced melanoma, and
other drugs using similar mechanisms
of action are following. However, both
treatments have limitations in that either
the proportion of responding patients
(ipilimumab) or the duration of res-
ponses (vemurafenib) is limited. For these
reasons, most patients with advanced
melanoma today still receive DTIC or
other chemotherapeutic agents sooner
or later in their course of the disease.
Until recently, chemotherapeutic drugs
have been studied only with respect to
their cytotoxic activity against tumor
cells, but evidence is accumulating that
at least some have broader activities and
should also be considered immunomo-
dulatory agents. In this regard, the study
of Hervieu et al (2012) in the current
issue of The Journal of Investigative
Dermatology is of high interest,
showing convincingly that DTIC is not
only a cytotoxic drug but that it also
exerts immunostimulatory effects. By
elegantly combining in vivo and in vitro
studies, the investigators demonstrate
that the antitumoral efficacy of DTIC
depends on the presence of cytotoxic
immune cells, specifically natural killer
(NK) cells and cytotoxic CD8þ T lym-
phocytes (CTLs). Analysis of the B16F10
mouse melanoma model revealed that
the antitumoral effect of DTIC was abso-
lutely dependent on IFN-g and was
abrogated by depletion of either NK
cells or CTLs. Accordingly, DTIC did
not mediate any antitumor effects in
T cell–deficient nude mice.
It has been reported that chemother-
apeutic agents can strengthen antitumor
immune responses either by attenuating
the immune suppression exerted by
T regulatory cells (Tregs) or myeloid-
derived suppressor cells (MDSCs), or
by enhancing activation of dendritic cells
(DCs) (Walter et al., 2012). However,
the investigators did not observe any
effect in DTIC-treated mice on the
frequency of Treg, MDSC, or DC
maturation. Rather, DTIC induced local
activation of NK and T cells, as assessed
by the expression of NKG2D and CD69
on both cell subsets in tumor-draining
lymph nodes. This suggested that the
tumor participated in the initiation of
immune responses, which could have
been attributable to the induction of
a so-called immunogenic cell death
detectable by the upregulation of calre-
ticulin expression on the tumor cells
(Kepp et al., 2011). However, in the
present study, no induction of a cell-
surface expression of calreticulin was
detected. Instead, the investigators ob-
served that DTIC treatment elicited the
expression of ligands of the immuno-
receptor NKG2D on melanoma cells.
Engagement of the ligands by NKG2D
on NK cells led to their activation, going
along with enhanced tumor-cell killing
and the release of IFN-g (Figure 1). This in
turn upregulated major histocompatibility
complex (MHC) class I expression on the
tumor cells, which favored their recogni-
tion by CTLs, owing to the upregulation
of MHC class I expression. Thus, upregu-
lation of NKG2DL by tumor cells
seemed to be the initial event of the
antitumor function of DTIC. Accord-
ingly, these antitumor effects were abro-
gated in the presence of blocking anti-
NKG2D antibodies.
Interestingly, similar results have been
reported for pancreatic cancer, with
Khallouf et al (2012) describing that
the anticancer effect of a biochemo-
therapy consisting of 5-fluorouracil (5-FU)
and IFN-a depends on the presence of
NK cells, CD8þ T cells, and DCs. The
investigators demonstrated that treatment
with 5-FU and IFN-a upregulates the
expression of NKG2D ligands on pan-
creatic cancer cells. Moreover, tumors
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Figure 1. Sequence of DTIC-induced antimelanoma immune responses. (a) Transplanted B16F10
melanoma in C57BL/6 mice is poorly killed by T and natural killer (NK) cells because of the low expression
or even the absence of major histocompatibility complex (MHC) class I molecules and ligands of activating
NK-cell receptors, respectively. (b) Dacarbazine (DTIC) treatment induces an upregulation of NKG2D
ligand (NKG2DL) expression on melanoma cells that initiates tumor-cell killing by NK cells. Activated NK
cells release significant amounts of IFN-g, which in turn induces MHC class I expression on neighboring
tumor cells. The enhanced MHC class I levels increase the efficiency of CTL cytotoxicity against melanoma
cells.
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of mice treated with 5-FU and IFN-a
harbored higher numbers of infiltrating
NK cells than those of control mice.
Hervieu et al (2012) observed the
upregulation of NG2D ligands not only
on mouse melanoma cells but also on
human melanoma cells, which renders
them vulnerable to NK-cell attack. The
exact mechanisms that are responsible
for the upregulation of NKG2D ligands
on tumor cells by certain drugs are
currently under intense investigation
(Rosental et al., 2012). Genotoxic agents
elicit a DNA-damage checkpoint res-
ponse initiated by ataxia telangiectasia
mutated (ATM) or ATM- and Rad3-
related protein kinases that have been
demonstrated to mediate NKG2DL
induction (Gasser et al., 2005). ATM in
turn activates p53, known as the central
transcriptional regulator of DNA-
damage responses. However, NKG2DL
upregulation in response to genotoxic
stress occurs independently of p53
(Gasser et al., 2005), although recent
studies have demonstrated that p53 has
a role in the control of ligand expres-
sion, pointing to the complexity of their
regulation (Heinemann and Paschen,
2012). The induction of NKG2DL ex-
pression has been observed for several
genotoxic agents, such as 5-FU and
cisplatin (Gasser et al., 2005; Khallouf
et al., 2012). The current report by
Hervieu et al (2012) is the first demon-
stration of such an effect for the drug
DTIC, and it provides evidence for
DTIC’s in vivo relevance in a murine
melanoma model. In humans, the in situ
expression of NKG2DL in melanoma
metastasis is quite heterogenous. In
comparison with primary tumors, meta-
stases seem to downregulate the NKG2DL
expression, suggesting that DTIC might
be an adequate tool to circumvent this
immune-escape mechanism (Vetter et al.,
2002).
Anticancer effects of
dacarbazine (DTIC)
include indirect immune
modulation.
The dependency of the anticancer
efficacy of DTIC on NKG2D ligand
upregulation and subsequent NK-cell
activation opens new avenues for the
identification of biomarkers predicting
the tumor response of melanoma
patients to DTIC treatment. This is of
high importance, as up to now there
have been no biomarkers available to
identify patients individually for DTIC
treatment. Thus, in the current treatment
algorithms for advanced melanoma, the
choice of DTIC is made arbitrarily. With
respect to the results of Hervieu et al
(2012), upregulation of NKG2D ligand
expression on the tumor cells of a
patient’s metastases after the first course
of DTIC, assessable by a tumor biopsy,
could serve as a predictive biomarker
for tumor response, which otherwise
is clinically detectable only after 2–3
treatment courses. Notably, we have
recently demonstrated that elevated
levels of soluble forms of NKG2DL are
detectable in the peripheral blood of
melanoma patients, which correlate
with poor prognosis (Paschen et al.,
2009). The latter could be explained
by the fact that the release of NKG2DL
protects tumor cells, at least in part, from
NK-mediated cytotoxicity. Nevertheless,
the course of the concentration of
soluble NKG2D ligands in the serum
of melanoma patients upon therapy with
DTIC may function as a predictive
biomarker of DTIC treatment response.
Indeed, there is a high need to define
suitable biomarkers predicting a mela-
noma patient’s individual response to
the treatment options that are currently
available. With such biomarkers, the
patient’s valuable survival time could
be spared by selecting treatments with
high probability of success, thus
providing ‘‘personalized medicine’’ for
melanoma.
Another interesting aspect of the
report by Hervieu et al (2012) is that it
provides a potential explanation for dis-
crepancies in tumor sensitivity toward
DITC in vitro and in vivo. In general,
chemotherapeutic agents can be tested
for their individual ex vivo efficacy on
fresh tumor material, and these results
correlate well with clinical tumor res-
ponses when patients are treated with
the respective agents (Ugurel et al.,
2006). However, this ex vivo test system
predicting chemotherapy responses does
not provide valid results for DTIC or its
derivative temozolomide, an observation
that could not be explained sufficiently
until now. In light of the present findings,
a new and striking explanation appears to
be that the ex vivo test assay quanti-
fying the chemosensitivity of melanoma
cell suspensions simply does not reflect
the impact of the immunity on the effects
of DTIC. Indeed, the systems used for
ex vivo chemosensitivity testing are
based on tumor-cell suspensions largely
depleted of immunologically active
cells, such as NK or T cells. The hypo-
thesis that DTIC requires the presence of
immune-competent cells would explain
why no ex vivo efficacy of DTIC on
tumor-cell suspensions was observed
using this test assay, despite a subse-
quently observed clinical response to
DTIC in the respective patients.
As initially indicated, treatment
responses to DTIC are limited. How-
ever, the study by Hervieu et al (2012)
provides a rationale for combining DTIC
as an immune-stimulating agent with
other immunotherapeutic agents, such
as ipilimumab. Thus, chemotherapeutic
agents are far from being ‘‘out of date’’,
and efforts to improve the understanding
of their exact mode of action are still
warranted.
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Melanoma Prognostics and
Personalized Therapeutics at a
Crossroad
Roger S. Lo1,2
Melanoma has recently emerged as a poster child for targeted therapies and
immunotherapies, with game-changing BRAF and immune checkpoint inhibitors
now in clinical trials and with approved clinical indications. One highly anticipated
use of novel therapeutic agents is in the adjuvant setting. Adjuvant BRAF and/or
immune checkpoint inhibition may positively affect the survival of melanoma
patients diagnosed at earlier stages but still at high risk for postsurgical relapses.
BRAF V600 mutations and, potentially, melanoma-associated immunity are pre-
dictive biomarkers for responses to these novel therapies. Emerging evidence
points to these predictive biomarkers doubling as prognostic biomarkers for high-
risk stage III patients, promising to help stratify these patients for the application
of novel adjuvant therapies.
Journal of Investigative Dermatology (2013) 133, 292–295. doi:10.1038/jid.2012.386
Inhibition of BRAF or immune checkpoint
in melanoma
Clinical exploitation of BRAF oncogene
addiction and tumor immunogenicity
in advanced melanoma has recently
culminated in the Food and Drug
Administration (FDA)’s approval of a
BRAF inhibitor (BRAFi), vemurafenib,
and an immune checkpoint inhibitor,
ipilimumab. This unprecedented success
has led to paradigm shifts in therapeutic
concepts (and in the design of clinical
trials). In the case of adenosine triphos-
phate-competitive small-molecule inhi-
bitors of mutant BRAF, success has meant
that the presence of BRAF V600 muta-
tions can predict partial (in the majority
of those treated) or complete (in a mino-
rity of those treated) melanoma shrink-
age in 50–60% of patients (Chapman
et al., 2011; Sosman et al., 2012). In
other words, the BRAF V600 mutation is
a therapeutic biomarker. Across the
board, in all melanoma patients with
BRAF V600 mutations, it is reasonable
to believe that the timing of intervention
at an advanced disease stage with overt
systemic involvement limits the initial
extent and the eventual durability of
clinical responses. Although not statisti-
cally significant, lower serum lactate
dehydrogenase before vemurafenib treat-
ment was associated with higher overall
responses (Jeffrey A. Sosman and Antoni
Ribas, personal communication). Thus,
BRAF inhibition earlier in the course of
disease may diminish the frequency of
partial initial responses and the almost
universal occurrence of acquired
(secondary) drug resistance. The mech-
anisms of BRAFi resistance are varied, but
often involve reactivation of the mitogen-
activated protein kinase (MAPK) signaling
pathway, with concomitant activation of
the RTK–PI3K–AKT signaling cascade
(Nazarian et al., 2010; Villanueva
et al., 2010; Poulikakos et al., 2011;
Wagle et al., 2011; Shi et al., 2012). On
the basis of the studies of BRAFi
resistance (Nazarian et al., 2010),
clinical trials are underway to test
combinations of targeted agents (e.g.,
against BRAF and its downstream kinase
MAPK/ERK kinase (MEK1/2) to prevent
or delay acquired BRAFi resistance.
In terms of immune checkpoint inhibi-
tors, the first success was with ipilimu-
mab, a monoclonal antibody targeting
the T-cell surface molecule called cyto-
toxic T-lymphocyte antigen 4 (CTLA-4).
CTLA-4 is a negative regulatory protein
that downregulates the priming phase
(i.e., lymph node) of antitumor immune
responses. Clinical inhibition of CTLA-4
by ipilimumab has delivered objective
response rates of about 10–15% among
metastatic melanoma patients. Although
this rate is lower than that achieved
with BRAFi, responses tend to be more
durable. In T cells, CTLA-4 competes
with the costimulatory receptor CD28
for binding to CD80 (B7-1) and CD86
(B7-2), which are expressed by antigen-
presenting cells. Other related T-cell-
negative regulatory receptors with
homology to the costimulatory CD28
receptor include program death-1 (PD-1),
B7-H4, and B- and T-lymphocyte atten-
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